Niemann-Pick type C1 (NPC1) disease is an autosomal recessive, fatal disorder characterized by a defect in cholesterol trafficking and progressive neurodegeneration. The disease is predominantly caused by mutations in the NPC1 gene; however, it has been assumed that heterozygous NPC1 mutations do not cause any symptoms. Here we demonstrate that cholesterol accumulation does not occur in young mouse brains; however, it does in aged (104 -106-week-old) NPC1؉/؊ mouse brains. In addition, Purkinje cell loss was observed in aged NPC1؉/؊ mouse cerebellums. Immunoblot analysis using anti-phospho-tau antibodies (AT-8, AT-100, AT-180, AT-270, PHF-1, and SMI-31) demonstrates the site-specific phosphorylation of tau at Ser-199, Ser-202, Ser-212, and Thr-214 in the brains of aged NPC1؉/؊ mice. Mitogen-activated protein kinase, a potential serine kinase known to phosphorylate tau, was activated, whereas other serine kinases, including glycogen synthase kinase 3␤, cyclin-dependent kinase 5, or stress-activated protein kinase/c-Jun N-terminal kinase were not activated. Cholesterol level in the lipid raft isolated from the cerebral cortices, ATP level, and ATP synthase activity in the cerebral cortices significantly decreased in the aged NPC1؉/؊ brains compared with those in the NPC1؉/؉ brains. All of these changes observed in NPC1؉/؊ brains were determined to be associated with aging and were not observed in the age-matched NPC1؉/؉ brains. These results clearly demonstrate that heterozygous NPC1 impairs neuronal functions and causes neurodegeneration in aged mouse brains, suggesting that human heterozygous NPC1 mutations may be a risk factor for neurodegenerative disorders, such as tauopathy, in the aged population.
Niemann-Pick type C1 (NPC1) 1 disease is an autosomal recessive disorder characterized by progressive neurodegeneration including ataxia, dystonia, seizures, and dementia (1) . In NPC1-deficient cells, exogenously transported and endogenously synthesized cholesterol accumulate in late endosome/ lysosomes, with delayed cholesterol transport to cellular compartments responsible for the regulation of intracellular cholesterol homeostasis (2) (3) (4) (5) . In addition to cholesterol, glycosphingolipids and other lipids accumulate in homozygous NPC1 brains with aging (1, 6) . The gene responsible for NPC1 disease, NPC1, was cloned in both humans and mice (7, 8) . It was previously demonstrated that NPC1 plays a key role in the transport of cholesterol to the trans-Golgi network, plasma membrane, and endoplasmic reticulum (9 -12) .
The neuropathological features of NPC1 brains are characterized by the loss of neurons such as Purkinje cells, hyperphosphorylated tau, and neurofibrillary tangle formation with the accumulation of lipid storage bodies and the presence of dendritic and axonal abnormalities (6, (13) (14) (15) (16) . These lines of evidence suggest that the intracellular accumulation of cholesterol and gangliosides correlates with the progression of NPC1 disease and induces neurodegeneration. However, there is a different viewpoint on the pathogenesis of NPC1 disease; i.e. the continuous defective use of cholesterol in NPC1 neural tissues causes tauopathy (6, 16, 17) . This notion is supported by previous studies showing that there is cholesterol deficiency in cellular compartments including distal axons (18) , although cholesterol accumulation occurs in the late endosome/lysosomal compartment (4, 5) due to a defect in the transport of cholesterol, the source of which is either endogenous synthesis or exogenous uptake.
With respect to neuronal gangliosides, a previous study supports the notion that the accumulation of gangliosides causes neurodegeneration (19) , whereas another study indicates that the accumulation of gangliosides is not the cause of neurodegeneration in NPC1 mice (20) . A recent study has demonstrated that impaired neurosteroidogenesis, due to disordered cholesterol trafficking, affects neuronal growth and differentiation and that allopregnanolone treatment delays the onset of neurological symptoms and lengthens the life of NPC1 mice (21) .
Our recent study has shown a novel mechanism underlying neurodegeneration in NPC1 disease, whereby an increased cholesterol level in mitochondrial membranes adversely affects mitochondrial membrane potential, the synthesis of ATP, and the level of cellular ATP in NPC1 mouse brains and neurons (22) . Since mitochondria are a key organelle for steroidogenesis, mitochondrial dysfunction may responsible for impaired neurosteroidogenesis. In addition, this also indicates that not whole-cell cholesterol level but rather compartment-or organelle-associated cholesterol level is critical for maintaining neuronal functions.
Note that NPC1 disease is an autosomal recessive disease, and heterozygous carriers of NPC1 mutations are not assumed to develop any neurological symptoms during their entire life span, and note that the effect of heterozygous NPC1 mutations on the development of neurological disorders has not been extensively investigated. This is also the case for NPC1ϩ/Ϫ mice. However, intermediate abnormalities in terms of cholesterol metabolism have been shown in nonneuronal cells from NPC1 patients (23) (24) (25) and in nonneuronal tissues or cells from NPC1ϩ/Ϫ mice (26 -28) . In addition, our recent study has demonstrated that NPC1ϩ/Ϫ exhibits intermediate dysfunction in the mitochondria of the brains of NPC1ϩ/Ϫ mice at 9 weeks of age (22) . These lines of evidence have led us to examine whether there occurs neuronal dysfunction or damage in NPC1ϩ/Ϫ mouse brains under certain conditions such as aging.
In this study, morphological and biochemical studies were performed on brains of aged heterozygous NPC1ϩ/Ϫ mice. In contrast to what has been assumed, neurodegeneration as demonstrated by Purkinje cell loss, enhanced phosphorylation of tau, and activated MAPK/ERK1/2 were clearly observed in NPC1ϩ/Ϫ mouse brains. It has been assumed that mutant NPC1 heterozygotes do not develop any clinical symptoms; however, these results suggest that heterozygous NPC1 mutations may be a risk factor for tauopathy. Since it is estimated that the incidence of NPC1 disease is as high as 1:150,000 (1), the percentage of the total population with the heterozygous NPC1 mutation is estimated to be around 0.5%. Thus, our present results show that heterozygous NPC1 mutations unexpectedly affect brains with aging and thus may lead to the investigation of the link between heterozygous NPC1 mutations and neurodegenerative diseases, such as Alzheimer disease.
EXPERIMENTAL PROCEDURES
BALB/c NPC1NIH Mice-The animal care and experiments using animals performed in this study were carried out in accordance with institutional guidelines. BALB/c mice carrying the genetic mutation for NPC1 were obtained from The Jackson Laboratory (Bar Harbor, ME). These heterozygous mice were bred to acquire NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice used in this study. The genotypes of the mice were determined from genomic DNA isolated from tail snip DNA using a PCR-based method and oligonucleotide primers described previously (7) . PCR products were separated using a 1.2% agarose gel. The mice used in this study ranged from 104 to 106 weeks of age.
Reagents-The monoclonal anti-phospho-independent tau antibody T46 was obtained from Zymed Laboratories, Inc. Histological Analysis-The mice were sacrificed by CO 2 inhalation and perfused intracardially with 0.1 M phosphate-buffered saline (PBS) containing heparin (50 units/ml). The brains were removed and fixed in 4% paraformaldehyde in PBS overnight at 4°C and then rinsed with PBS and cryoprotected in a solution of 30% sucrose in PBS. Fixed tissues were sectioned on a semimotorized rotary microtome (LEICA RM2145, Wetzlar, Germany) at 30 m and processed for immunohistochemistry with the anti-calbindin D28K (1:500) and AT8 (1:500). Immunoreactivity was detected with diaminobenzidine using the ABC Elite kit according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA). For cresyl violet staining, slides were immersed in 70, 80, and 95%, ethanol for 5 min each and in 100% ethanol for 5 min and then in xylene for 15 min. The slides were then sequentially immersed back in 100, 95, and 70% ethanol solutions and distilled water for 5 min in each. The slides were stained for 1 min in filtered cresyl violet solution and then briefly rinsed twice in distilled water. They were then sequentially dehydrated again in 70, 80, 95, and 100% ethanol solutions for 2 min each. The slides were placed in xylene for another 10 min and then mounted with Permount. For double fluorescence staining, the sections were treated overnight with calbindin D28K antibody (1:500) and AT-8 antibody (1:500) at 4°C overnight, followed by incubation with second antibodies, rhodamine-conjugated goat anti-rabbit IgG (Chemicon International, Temecura, CA) diluted at 1:500, and fluorescein isothiocyanate-conjugated goat anti-mouse IgG (American Qualex, San Clemente, CA) diluted at 1:50, for 1 h at room temperature. The slides were then washed with PBS and mounted with Vectashield (Vector). For costaining with calbindin D28K antibody and filipin, the sections were incubated overnight with calbindin D28K antibody (1:500) at 4°C overnight, followed by washing three times for 5 min each using 100 g/ml filipin in PBS and then incubated with rhodamine-conjugated goat anti-rabbit IgG (1:500) for 1 h at room temperature. The slides were then washed with PBS and mounted with Vectashield (Vector). Fluorescent images were obtained using a model LSM 510 laser-scanning confocal microscope (Zeiss) equipped with a ϫ 63 Plan Apochromat numerical aperture and a 1.4 oil immersion objective.
Protein Preparation-The mice were sacrificed by CO 2 inhalation, and their brains were harvested, rinsed in PBS, and immediately frozen in liquid nitrogen. The cerebrum and cerebellum were separated and homogenized in 10 volumes of Tris-saline (50 mM Tris-HCl (pH 7.4) and 150 mM NaCl), containing protease inhibitors (Complete TM ) and phosphatase inhibitors (10 M NaF and 1 mM orthovanadate) using a motordriven Teflon homogenizer. The homogenates were centrifuged at 3,000 ϫ g for 10 min at 4°C, and the supernatants were stored for biochemical analyses. Protein concentration was determined using the bicinchoninic acid protein assay kit (Pierce).
Determination of ATP Level-ATP level in mouse brain tissues was determined as previously reported (22) . In brief, the homogenates of cerebrum and cerebellum were centrifuged at 10,000 rpm for 2 min at 4°C and then rinsed three times with PBS. ATP level in these samples was determined using the ATP Bioluminescence Assay kit CLS II (Roche Applied Science). In brief, the pellet was resuspended in 50 l of ice-cold ATP lysis buffer (100 mM Tris and 4 mM EDTA, pH 7.75), to which 150 l of boiling ATP lysis buffer was added, and the samples were incubated for 2 min at 99°C. The samples were centrifuged at 10,000 rpm for 1 min at 4°C, and the supernatants were collected. Finally, the ATP level was determined by combining 50 l of the supernatant with 50 l of the luciferase reagent. After a 20-s delay, chemiluminescence was measured with a 2.6-s integration time using a microplate luminometer (EG&G Berthold, Bad Wildbad, Germany). Luciferase activity was expressed in fluorescence units/g of protein.
Determination of ATP Synthase Activity-Brain mitochondria were isolated as previously reported (22) . For the determination of ATP synthase activity, 100 g of mitochondrial protein from each sample was used to measure the rate of ATP synthesized. The reaction was initiated by adding 100 g of mitochondrial protein into 100 l of reaction buffer (10 mM K 2 HPO 4 (pH 7.4) 300 mM D-mannitol, 10 mM KCl, and 5 mM MgCl 2 ) at 37°C. After 1 min, 10 l of ADP (50 M) was added, and the intensity of bioluminescence was recorded at 37°C, where peak height was proportional to the amount of ATP synthesized.
Immunoblot Analysis-Equal amounts of proteins separated using 4Ϫ20% gradient Tris/Tricine SDSϪPAGE (Dai-ichi Pure Chemical Co., Ltd., Tokyo, Japan) were electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). Nonspecific binding was blocked with 5% fat-free milk in phosphate-buffered saline containing 0.1% Tween 20. The blots were then incubated with primary antibodies overnight at 4°C. For the detection of both monoclonal and polyclonal antibodies, appropriate peroxidase-conjugated secondary antibodies were used in conjunction with SuperSignal chemiluminescence (Pierce) to obtain images on the film.
Preparation of Raft Fractions-Detergent-insoluble membrane raft fractions were obtained according to the established method previously reported (6) . One milliliter of each fraction was sequentially collected from the top of the gradient. The extraction of lipids and the subsequent determination of the amounts of cholesterol and phospholipids in each sample were carried out according to previously described methods (29) .
Lipid Analysis-The levels of cholesterol and phospholipids in the samples were determined using enzymatic methods. Cholesterol level was determined using a cholesterol determination kit, LTCII (Kyowa Medex, Tokyo), whereas phospholipid level was determined using a phospholipid determination kit, PLB (Wako, Osaka, Japan).
Detection of GM1 Ganglioside-For the detection of GM1 ganglioside, samples from each fraction were dissolved in equal volumes of Laemmli buffer. They were then subjected to 4 -20% gradient Tris/Tricine SDS-PAGE (Dai-ichi Pure Chemical Co., Ltd.). The separated GM1 ganglioside was transferred onto an Immobilon or polyvinylidene difluoride membrane (Millipore) with a semidry electrophoretic transfer apparatus (Nihon Eido, Tokyo, Japan) using a transfer buffer (0.1 M Tris, 0.192 M glycine, and 20% methanol). The membranes were blocked with 5% fat-free milk in PBS containing 0.1% Tween 20 for 1 h and probed with horseradish peroxidase-conjugated cholera toxin B (Sigma) (final concentration of 42 ng/ml) overnight at 4°C. In between steps, the membranes were washed four times with PBS-T for 15 min. Bound cholera toxin was detected using Super Signal Chemiluminescence (Pierce).
Statistical Analysis-Statistical analysis was carried out using StatView computer software (Macintosh version 5.0, Abacus Concepts Inc., Berkeley, CA). A p value of Ͻ0.05 was considered to be significant.
RESULTS
Cholesterol Accumulation in Brains of Aged NPC1 Heterozygous Mouse-The brains of NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 24, 40, and 104 -106 weeks of age were isolated, and the levels of cholesterol and phospholipids were determined. The cholesterol levels in the cerebrum and cerebellum of the NPC1ϩ/Ϫ mice were significantly elevated compared with those in the same brain areas of the NPC1ϩ/ϩ mice at 104 -106 weeks of age (Fig. 1a) , whereas the cholesterol levels were similar in the two groups at 24 and 40 weeks of age (Fig. 1a) . The phospholipid levels were similar in the two genotypes at every age examined (Fig. 1b) . The filipin and calbindin staining of brain samples (the third lobe of each cerebellum) prepared from the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 104 weeks of age shows that cells exhibiting a strong filipin-positive signal in the NPC1ϩ/Ϫ cerebellar section (from the third lobe) are also calbindin-positive, whereas the calbindin-positive cells in the NPC1ϩ/ϩ cerebellar section exhibit a very weak signal for filipin staining (Fig. 1c) . These results indicate that cholesterol accumulation occurs in Purkinje cells of aged NPC1ϩ/Ϫ mouse cerebellum.
Purkinje Cell Loss in Aged NPC1 Heterozygous Mice-The cerebellums of NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 104 -106 weeks of age were immunohistochemically analyzed using the anti-calbindin antibody, which specifically recognizes Purkinje cells. The number of anti-calbindin antibody-positive cells decreased in the NPC1ϩ/Ϫ cerebrum (Fig. 2, d-f ) compared with that in the NPC1ϩ/ϩ cerebellum (Fig. 2, a-c) , suggesting that Purkinje cell loss occurred in the aged NPC1ϩ/Ϫ cerebellum. However, this was not the case for the NPC1ϩ/Ϫ cerebellum at 24 and 40 weeks of age (data not shown). Next, the number of anti-calbindin antibody-positive cells in each lobe of the cerebellums of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 104 -106 weeks of age was determined. The number of Purkinje cells was significantly decreased in first ϩ second, third, seventh, and eighth lobes of NPC1ϩ/Ϫ cerebellum compared with those of NPC1ϩ/ϩ cerebellum (Fig. 2g) .
Hyperphosphorylation of Tau in NPC1ϩ/Ϫ Mouse BrainSince neurodegeneration found in the NPC homozygous mouse brain is accompanied by hyperphosphorylated tau (6, 16) , the sagittal sections of the brains were immunohistochemically stained using the anti-phospho-tau antibody AT-8. AT-8 stained neurons strongly in the cerebral cortices and hippocampus of the NPC1ϩ/Ϫ mice (Fig. 3, b and d) compared with those of the NPC1ϩ/ϩ mice (Fig. 3, a and c) . For cerebellar sections, double staining using anti-calbindin antibody was performed. The Purkinje cells demonstrated as being calbindin-positive were very faintly stained with AT-8 in the aged NPC1ϩ/Ϫ mouse cerebellum, whereas calbindin-positive Purkinje cells were also AT-8-positive in the aged NPC1ϩ/ϩ mouse cerebellum (Fig. 3, e-h ). The ratio of AT-8-positive Purkinje cells to total Purkinje cells was very high in NPC1ϩ/Ϫ mouse cerebella compared with that of NPC1ϩ/ϩ mouse cerebella (Fig. 3i) .
To verify that the histologic abnormalities are a result of enhanced tau phosphorylation, immunoblot analysis was conducted using lysates of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ cerebrums and cerebellums. The antibodies used were T-46, which recognizes phospho-independent tau; AT-8, AT-100, AT-180, AT-270, PHF-1, and SMI-31, which recognize site-specific phosphorylation of tau; and the anti-␤-tubulin antibody as an internal standard. The intensities of the signals corresponding to phosphorylated tau demonstrated by AT-8 and AT-100 increased in the cerebrum and cerebellum of the NPC1ϩ/Ϫ mice at 104 -106 weeks of age compared with those for the NPC1ϩ/ϩ mice of at the same age (Fig. 4a) . However, the intensities of the signals The results represent the mean Ϯ S.E. of three different samples and are representative of three independent experiments. c, brain sections from the third lobes of each cerebellum of NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 104 weeks old were subjected to filipin and calbindin staining as described under "Experimental Procedures" and visualized using confocal laser microscopy. Purkinje neurons demonstrated as calbindinpositive cells in NPC1ϩ/Ϫ mouse cerebellum were strongly stained with filipin, whereas those in NPC1ϩ/ϩ mouse cerebellum were only weakly stained. Scale bar, 25 m. demonstrated by AT-180, AT-270, PHF-1, and SMI-31 did not differ between samples from the NPC1ϩ/ϩ and NPC1ϩ/Ϫ brains (Fig. 4a) . The phosphorylation site of tau in the cerebrums and cerebellums of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 24 and 40 weeks of age was also determined (Fig. 4, b and c,  respectively) . The phosphorylation state of tau and the total tau level in both samples demonstrated by AT-8 and T-46 did not differ between the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice (Fig. 4, b  and c) .
MAPK Was Activated in NPC1ϩ/Ϫ Mouse Brains-Since our previous reports demonstrated that tau phosphorylation in NPC1-deficient cells is caused by enhanced MAPK activity (6, 17) , the activity of tau kinases including MAPK was determined. Among the kinases examined, including MAPK/ ERK1/2, GSK-3␤, JNK, and Cdk5/p25, the levels of phospho-MAPK/ERK1/2 in the cerebrum and cerebellum of the NPC1ϩ/Ϫ mice at 104 -106 weeks of age increased compared with those for the NPC1ϩ/ϩ mice (Fig. 5a) , whereas the levels of phospho-GSK-3␤, -JNK, and Cdk5/p25 remained unchanged (Fig. 5, b, c, and d) . The activities of MAPK/ERK1/2 in the cerebrums and cerebellums of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 24 and 40 weeks of age were also determined. The activities of MAPK/ERK1/2 in both samples did not differ between the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice (Fig. 5, e and f) .
Cholesterol Level in Lipid Rafts Decreased in NPC1ϩ/Ϫ Mouse Brains-Because the enhanced MAPK/ERK1/2 activity due to the decreased cholesterol level in the lipid rafts is suggested to induce tau phosphorylation in NPC1Ϫ/Ϫ mouse brains and NPC1Ϫ/Ϫ cells (6, 17) , lipid compositions in the raft fractions isolated from the cerebral cortices of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice were analyzed. The raft marker GM1 ganglioside was recovered in fractions 4 and 5, and another raft marker, flotillin-1, was recovered in fraction 5 (Fig. 6c) . The cholesterol levels in fractions 4 and 5 isolated from the NPC1ϩ/Ϫ brain were significantly lower than those in the same fractions isolated from the NPC1ϩ/ϩ brain (Fig. 6a) , whereas the levels of phospholipids in these fractions showed no significant difference between the two genotypes (Fig. 6b) .
Level of ATP in NPC1ϩ/ϩ and NPC1ϩ/Ϫ Brains-Our previous study demonstrated that ATP levels in NPC1Ϫ/Ϫ organs including the brain, liver, and muscles as well as in NPC1Ϫ/Ϫ cultured neurons decrease compared with those in NPC1ϩ/ϩ organs and neurons (22) ; thus, ATP level and ATP synthase activity in the aged NPC1ϩ/ϩ and NPC1ϩ/Ϫ brains were determined. As shown in Fig. 7 , ATP levels in the cerebrum and cerebellum of the NPC1ϩ/Ϫ mice at 104 -106 weeks of age significantly decreased compared with those in the same brain areas of the NPC1ϩ/ϩ mice (Fig. 7a) . ATP synthase activity in the cerebellum of the aged NPC1ϩ/Ϫ mice also decreased compared with that of the aged NPC1ϩ/ϩ mice (Fig. 7b) .
DISCUSSION
Here we demonstrate for the first time the unexpected phenomenon that neurodegeneration occurs in aged NPC1ϩ/Ϫ mouse brains. This neuronal damage is accompanied by tau hyperphosphorylation and enhanced MAPK/ERK1/2 activity, which are observed in young NPC1Ϫ/Ϫ mouse brains and NPC1Ϫ/Ϫ cells (6, 17) . The significant accumulation of cholesterol in neurons in the brain and the significant reduction in cholesterol level in raft fractions isolated from aged NPC1ϩ/Ϫ cerebrums were also observed. These changes are found to depend on aging in NPC1ϩ/Ϫ mice. NPC1 disease is a hereditary disorder that develops in an autosomal recessive manner; thus, it has been assumed that heterozygous carriers of NPC1 mutations do not develop any neurological symptoms during their entire life span (1) . It has also been presumed that this is the case for NPC1ϩ/Ϫ model mice. Therefore, little attention has been paid to whether NPC1ϩ/Ϫ mice develop any symptoms with aging. To our surprise, however, the present study has clearly shown that neurodegeneration demonstrated as Purkinje cell loss accompanied by intracellular cholesterol accumulation and its deficiency in lipid rafts occurs in the aged NPC1ϩ/Ϫ mouse brain. A few studies have investigated NPC1 heterozygotes and have shown that NPC1 heterozygotes have "intermediate" abnormalities in cholesterol metabolism at the nonneuronal cell level (23, 26, 27) ; however, it has been shown that there is no significant abnormality in terms of cholesterol metabolism in cultured NPC1ϩ/Ϫ neurons (30) and young NPC1ϩ/Ϫ brains (6) . These lines of evidence suggest that cholesterol metabolism in the central nervous system changes and neurodegeneration accompanied by abnormal tau phosphorylation occurs only in aged NPC1ϩ/Ϫ mice. The reason for the change in cholesterol metabolism found only in the aged NPC1ϩ/Ϫ brains may be the expression of the NPC1 protein in NPC1ϩ/Ϫ brains being approximately half that in NPC1ϩ/ϩ brains (6), which may FIG. 4 . Immunoblot analysis of tau in cerebrum and cerebellum of 104 -106-week-old NPC1؉/؉ and NPC1؉/؊ mice. a, equal amounts of postnuclear supernatant protein from the cerebrum and cerebellum were subjected to immunoblot analysis using the site-specific phospho-tau antibodies AT-8, AT-100, AT-180, AT-270, PHF-1, and SMI-31 in addition to an antibody that recognizes phospho-independent tau, T46, and the anti-␤-tubulin antibody as an internal standard. Tau in the cerebrum and cerebellum of 24-week-old (b) and 40-week-old (c) NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice was immunohistochemically analyzed using AT-8 and AT-100 antibodies.
FIG. 5.
Immunoblot analysis of taudirected kinases in cerebrum and cerebellum of 104 -106-week-old NPC1؉/؉ and NPC1؉/؊ mice. Equal amounts of postnuclear supernatant protein from the cerebrum and cerebellum were subjected to immunoblot analysis using the monoclonal antibodies specific for pan-ERK1/2 and phospho-ERK (p-ERK) (a), pan-GSK-3␤ and phospho-GSK-3␤ (p-GSK-3␤) (b), pan-SAPK/JNK and phospho-SAPK/JNK (p-SAPK/JNK) (c), and Cdk5 (d). Immunoblot analysis of ERK1/2 in the cerebrum and cerebellum of 24-week-old (e) and 40-week-old (f) NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice was performed using anti-pan-ERK and anti-phospho-ERK antibodies.
very slightly affect cellular cholesterol trafficking. As a result, it takes a longer time for neurons to show any abnormalities in terms of cholesterol accumulation in the late endosome/lysosome compartment and the subsequent shortage of cholesterol in other compartments. Since a decreased cellular cholesterol level stimulates MAPK activity (17, 31) and tau phosphorylation (32) , it is reasonable to postulate that a reduced cholesterol level in lipid rafts, due to impaired cholesterol trafficking, increases MAPK activity and enhances tau phosphorylation in aged NPC1ϩ/Ϫ brains. This is the case for younger NPC1Ϫ/Ϫ brains; i.e. neurodegeneration in NPC1Ϫ/Ϫ brains is linked with an increased MAPK activity and enhanced tau phosphorylation induced by a sustained cholesterol shortage due to the absence of its trafficking (6, 17) .
In addition, it is likely that impaired cholesterol trafficking and the resultant intracellular cholesterol accumulation may result in an increased cholesterol level in mitochondria, which induces mitochondrial dysfunction, thereby affecting ATP synthase activity and reducing cellular ATP level, because, as we have reported, both increased and decreased cholesterol level in the mitochondrial membrane cause mitochondrial dysfunction and reduce cellular ATP level, which causes neurodegeneration in the younger NPC1Ϫ/Ϫ mice (22) . With these results taken together, it is possible that the altered cellular cholesterol metabolism enhances tau phosphorylation and decreases cellular ATP level, both of which synergistically or independently induce neuronal neurodegeneration. One may raise the questions of what causes neurodegeneration, enhanced tau phosphorylation or low ATP level, and whether these two pathways work independently or dependently. The present study cannot answer these questions. Previous studies demonstrated that mitochondrial dysfunction with energy depletion causes cell death (33, 34) and that tau abnormalities alone can cause neurodegenerative diseases (35, 36) , indicating that each pathway can independently cause neuronal death. However, previous studies showed that there is a correlation between ATP level and the activity of tau kinases including MAPK/ERK1/2 (37, 38) . These results enable us to assume that mitochondrial dysfunction with a decreased ATP level and the enhancement of tau phosphorylation synergistically contribute to neurodegeneration in aged NPC1ϩ/Ϫ mouse brains.
Finally, the results of our present study, contrary to what has been assumed, suggest that heterozygous NPC1 mutations are a risk for neuronal impairment. Since the ratio of the population with heterozygous NPC1 mutations is estimated to be as high as 0.5% (1), our findings lead us to further examine whether heterozygous NPC1 mutations are a risk for tauopathy, including Alzheimer disease. These issues should be addressed in future studies. Two independent experiments show similar results. b, the ATP synthase activities in mitochondria isolated from cerebrum and cerebellum of the NPC1ϩ/ϩ and NPC1ϩ/Ϫ mice at 104 -106 weeks of age was determined. The fraction containing purified brain mitochondria was isolated as described previously (22) . The enzymatic analysis was performed by measuring the rate of ATP synthesis from ADP (ATP synthesis). The results represent the mean Ϯ S.E. of five different samples and are representative of two independent experiments. *, p Ͻ 0.05.
